EUSA licenses from Alize's L-asparaginase to complement Erwinaze for ALL
This article was originally published in Scrip
Executive Summary
EUSA Pharma, a private equity backed specialty pharmaceutical company focused on oncology, has acquired the exclusive worldwide development and commercialisation rights to a new L-asparaginase product in Phase I development, Asparec, from the French company Alize Pharma.